Stone T W
Institute of Biomedical and Life Sciences, University West Medical Building, University of Glasgow, Glasgow G12 8QQ, UK.
Prog Neurobiol. 2001 Jun;64(2):185-218. doi: 10.1016/s0301-0082(00)00032-0.
In just under 20 years the kynurenine family of compounds has developed from a group of obscure metabolites of the essential amino acid tryptophan into a source of intensive research, with postulated roles for quinolinic acid in neurodegenerative disorders, most especially the AIDS-dementia complex and Huntington's disease. One of the kynurenines, kynurenic acid, has become a standard tool for use in the identification of glutamate-releasing synapses, and has been used as the parent for several groups of compounds now being developed as drugs for the treatment of epilepsy and stroke. The kynurenines represent a major success in translating a basic discovery into a source of clinical understanding and therapeutic application, with around 3000 papers published on quinolinic acid or kynurenic acid since the discovery of their effects in 1981 and 1982. This review concentrates on some of the recent work most directly relevant to the understanding and applications of kynurenines in medicine.
在不到20年的时间里，犬尿氨酸类化合物已从必需氨基酸色氨酸的一组鲜为人知的代谢产物发展成为深入研究的对象，其中喹啉酸在神经退行性疾病，尤其是艾滋病痴呆综合征和亨廷顿舞蹈症中被假定发挥作用。犬尿氨酸之一的犬尿喹啉酸，已成为用于识别释放谷氨酸的突触的标准工具，并已作为几组正在开发用于治疗癫痫和中风的化合物的母体。犬尿氨酸类化合物在将一项基础发现转化为临床理解和治疗应用来源方面取得了重大成功，自1981年和1982年发现其作用以来，已发表了约3000篇关于喹啉酸或犬尿喹啉酸的论文。本综述集中于一些与理解犬尿氨酸类化合物在医学中的应用最为直接相关的近期研究。
